CN1033738C - Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing same - Google Patents

Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing same Download PDF

Info

Publication number
CN1033738C
CN1033738C CN87104963A CN87104963A CN1033738C CN 1033738 C CN1033738 C CN 1033738C CN 87104963 A CN87104963 A CN 87104963A CN 87104963 A CN87104963 A CN 87104963A CN 1033738 C CN1033738 C CN 1033738C
Authority
CN
China
Prior art keywords
csf
acid
molecular weight
polyoxyethylene
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN87104963A
Other languages
Chinese (zh)
Other versions
CN87104963A (en
Inventor
町田实
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN87104963A publication Critical patent/CN87104963A/en
Application granted granted Critical
Publication of CN1033738C publication Critical patent/CN1033738C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A stable granulocyte colony stimulating factor-containing pharmaceutical preparation contains, in addition to granulocyte colony stimulating factor as an active agent, at least one substance selected from a pharmaceutically acceptable surfactant, saccharide, protein and high-molecular weight compound.

Description

The stable pharmaceutical and the production method thereof that contain granulocytosis colony stimulative factor
The invention relates to a kind of preparation that contains granulocytosis colony stimulative factor.Special and a kind of stable pharmaceutical that contains granulocytosis colony stimulative factor of the present invention is relevant, this medicament can prevent active component (for example granulocytosis colony stimulative factor) because the absorption of dress product wall, or combination, polymerization and even oxidation and inactivation or lose.
Chemotherapy is the multiple a kind of method that catches of treatment, but finds recently, changes furuncle and can cause for example formation of fastbacteria of some serious clinical problem, variation of pathogen and the serious effect of paying.Therefore these problems for fear of relevant with chemotherapy comprise for example antibiotic, and the application of chemotherapeutics such as antibacterial is wanted to adopt a kind ofly can activate the material that the infectious bacteria host gives anti-ability, thereby aforementioned chemotherapy problem can all be solved.Give in the anti-ability host multiple, leukocyticly engulf bacterial action and it is believed that at the initial stage of bacterial infection influence is the strongest, it is contemplated that therefore differentiation comes to the ripening period and can strengthen host's anti-infection ability greatly by promoting the growth of neutrophilic leukocyte.(G-CSF) is a kind of ten minutes utility with above-mentioned effect to granulocytosis colony stimulative factor, and same assignee's past attempts of the present invention was submitted a relevant patent (Japanese patent application No23777/1985) of G-CSF as a kind of anti-infective of utilizing.
Therefore as mentioned above, current chemotherapy of carrying out exists multiple unavoidable problem, is adopting as possible to activate the medicine that host or infected patient give anti-ability.Indubitable, G-CSF itself has the ability that the activation host gives anti-effect, but also finds, if with its with can activate a kind of material that the host gives anti-ability and merge and be applied to clinically, G-CSF then has great curative effect.
G-CSF consumption is few, and G-CSF content is that the drug dose of 0.1-500 micrograms (being preferably 5-50 micrograms) is generally each adult 1-7 times weekly.For example ampoule or injector wall absorb by container but G-CSF is easy to.Therefore if medicine is injected with this aqueous solution form, just it can be adsorbed on its container for example on ampoule or the injector wall.So make G-CSF can not fully show the activity of medicine, the also feasible G-CSF that must add cushion owing to adsorb the loss result that may cause.
In addition, G-CSF instability is to environmental factors temperature for example, humidity.Oxygen and ultraviolet are extremely sensitive.Because the effect of these factors, physics or chemical change can take place in G-CSF, for example combination, polymerization and oxidation and loss of activity greatly.If with the ten minutes accurate way, very little take G-CSF, these phenomenons can cause being difficult to play fully therapeutical effect.
Therefore need development a kind of stable G-CSF medicament, it can fully prevent the active decline of its active component.Here it is provides the main target of the present invention of a kind of stable G-CSF medicament.
The inventor has carried out deep research in order to improve the stability that contains G-CSF medicament, and if find to add pharmaceutically useful surfactant, saccharide, protein or high-molecular weight compounds then can effectively reach this purpose.
Therefore, the invention is characterized in and contain G-CSF and be selected from least a material that to do in medicinal surfactant, saccharide, protein and the polymer substance.
Adopt for example Japanese patent application NO153273/1984, any method of 269455/1985,269456/1985,270833/1985,270839/1985 description can obtain containing the medicament of the present invention of C-CSF.A kind of cell strain (CNCM registration number I-315 or I-483) that for example can be by cultivate suffering from oral cancer patient oncocyte or in a kind of appropriate host cell (for example escherichia coli, C127 cell or Chinese hamster ovary cell) prepare G-CSF of people by recombinant DNA (adopting people G-solid acting on of CSF coding base to prepare) expression.
Any highly purified human G-CSF can add in the medicament of the present invention as G-CSF.G-the GSF of separation of human from the cultured cell supernatant of a kind of generation people G-CSF preferably, and obtain active polypeptide of a kind of people of having G-CSF or glycoprotein the host that can transform from the recombinant vector of a kind of people of containing G-CSF active polypeptide encoding gene.
Two routine best G-the CSF example is as follows: (1) has the molecular weight of the people G of following physicochemical properties-CSF:i): adopt dodecyl sodium sulfate-poly-propionic acid amide. gel electrophoresis determining molecular weight to be approximately 19,000 ± 1,000.Ii) isoelectric point, IP: in PI=5.5 ± 0.1, having one in the isoelectric point, IP of PI=5.8 ± 0.1 and PI=6.1 ± 0.1 3 at least is its isoelectric point, IP.Iii) uv absorption: obtained the maximum absorption is at 280nm, and the minimal absorption value is at 250nm.Iv) 21 residue amino acid sequences of N-terminal are:
H 2N-Soviet Union-dried meat-bright-Gan-dried meat-third-Si-Si-bright-dried meat-glutamine-Si-phenylpropyl alcohol-bright-bright-Lai-Guang-bright-Gan-glutamine-figured silk fabrics-(2) human G-CSF or have the active peptide species of people's granulocyte stimulating factor, this polypeptide are partly or entirely to express with following aminoacid sequence.Or a kind of a kind of glycoprotein of chatting a polypeptide and a sugar chain part to some extent that contains.(Met) nThr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu ( Val Ser Glu ) mCys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ( m01； And n is 0 or 11).
The detailed method for preparing this two class G-CSF is seen Japanese patent application No153273/1984,269455/1985, and 269456/1985/, 270838/1985 and 270839/1985 description, all these are all submitted by the assignee of the present invention.
Another method that can adopt is that the cell and the outgrowth malignant cell of a kind of oneself that produce G-CSF are merged, and cultivates the hybridoma that obtains then under the condition that is added with or is not added with cytokinin.
As requested, adopt any known method further purify and concentrate after the people G-CSF solution that contains that obtains can freezingly preserve, perhaps behind the freeze-drying and dehydrating, can preserve this solution.
In order to obtain containing the stable pharmaceutical of G-CSF, the process that can adopt the present invention to mention specially prepares all these people G-CSF.
Being used for the surfactant exemplary that the present invention contains G-CSF stable pharmaceutical is described below: the non-ionic surface active agent with 6-18HLB, for example sorbitan fatty acid esters is (as the sad monoesters of sorbitan, sorbitan lauric acid monoesters, with sorbitan Palmic acid monoesters), fatty acid glyceride (caprylic acid monoester for example, glycerol myristic acid monoester and glycerol hard fatty acids monoesters), polyglyceryl fatty acid ester (ten glycerol hard fatty acids monoesters for example, ten glycerol hard fatty acids dibasic acid esters, with ten glycerol linoleic acid monoesters), polyoxyethylene sorbitan fatty acid esters is (as polyoxyethylene sorbitan lauric acid monoesters, polyoxyethylene sorbitan oleic acid monoester, polyoxyethylene sorbitan hard fatty acids monoesters, the polyoxyethylene sorbitan cetylate, polyoxyethylene sorbitan oleic acid three esters and polyoxyethylene sorbitan, hard fatty acids three esters), Polyoxyethylene Sorbitol Fatty Acid Esters is (as polyoxyethylene sorbitol hard fatty acids four esters, with polyoxyethylene sorbitol oleic acid four esters), polyethylene fatty acid glyceride (as polyoxyethylene glycerol hard fatty acids monoesters), polyethylene glycol fatty acid ester (as polyethylene glycol hard fatty acids diester), polyoxyethylene alkyl ether (as polyoxyethylene laurel ether), polyoxyethylene polyoxy-propylene is (as polyoxyethylene polyoxypropylene glycol ether, polyoxyethylene polyoxypropylene propyl ether and polyoxyethylene polyoxypropylene cetyl ether), polyoxyethylene alkylphenyl group ether (as the polyoxyethylene nonyl ethers), polyoxyethylene castor oil, the hard Oleum Ricini of polyoxy ethyl (polyoxy ethyl castor oil hydrogenated), polyoxy ethanol Cera Flava derivant (as polyoxy ethyl sorbitol Cera Flava), Wool wax alcohols,ethoxylated derivant (as Wool wax alcohols,ethoxylated) and polyoxyethylene fatty acid amide (as polyethylene hard fatty acids amide); Non-ionic surface active agent for example has a C 10-C 18The alkyl sulfate of alkyl, (as sodium hexadecyl sulfate, sodium lauryl sulphate and oily sodium sulfate) polyoxyethylene alkyl ether sulfate salt, wherein oxygen ethylene average mol number is 2-4, and alkyl has 10-18 carbon atoms (as the polyoxyethylene sodium lauryl sulphate), the alkylthio succinate, wherein alkyl has 8-18 carbon atoms (as dodecyl esters of sulfosuccinic acids sodium); The neutral surface active agent, lecithin for example, glycerol phosphate, cephalin (as sphingomyelin), and sucrose fatty acid ester, wherein fatty acid has 12-18 carbon atoms.Certainly these tables and activating agent both can use separately also and can mix use.
The preferably per by weight 1 part of G of the dosage of surfactant of listing above-CSF 1-10000 part activating agent.
Being used for the present invention preparation contains and stablizes the saccharide that G-the CSF medicament is used and can select to do the medicinal monosaccharide that has, oligosaccharide and polysaccharide and phospholipid and nucleotide derivative.Exemplary is as follows; The sucrose alcohol of trivalent and Geng Gao, glycerol for example, erithritol, arabitol, xylitol, sorbitol and mannitol; Acid sugar is glucuronic acid for example, iduronic acid, neuraminic acid, galacturonic acid, gluconic acid, mannuronic acid, the glucose keto acid, galactose keto acid and gulose keto acid, hyaluronic acid and salt thereof, chondroitin sulfate and salt thereof, also has heparin, inulin, chitin and derivant thereof, dextrin, mean molecule quantity are 5000-150000 glucosan and alginic acid and salt thereof.No matter be single with or share, all these saccharides all are useful.
The saccharide consumption of listing above, 1 portion of G-CSF1-10000 portion sugar preferably by weight.
Be used for the protein exemplary that the present invention contains the G-CSF stable pharmaceutical and comprise the human serum albumin, human serum globulin, gelatin, gelatin (mean molecule quantity=7000-100 of acid treatment, 000), gelatin of alkali treatment (mean molecule quantity=7000-100,000) and collagen protein.Indubitable, these albumen both can be singly with also mixing usefulness.
Above listed protein consumption by weight every part of G-CSF can add 1-20,000 part.
Can be used for the macromolecular compound exemplary that the present invention contains G-CSF stable pharmaceutical and comprise for example hydroxypropyl cellulose of natural polymer, hydroxy methocel, sodium carboxymethyl cellulose and hydroxyethyl-cellulose; Synthetic polymer is polyethylene ethanedioic acid (molecular weight=300-6,000) for example, polyvinyl alcohol (molecular weight=20,000-100,000) and polyvinylpyrrolidone (molecular weight=20,000-100,000).Indubitable these macromolecular compounds both can be singly with also merging use.
The optimum dose of listing in top high-molecular weight compounds every part of G-CSF by weight adds 1-20,000 part.
Except above-mentioned surfactant, outside saccharide, protein or the macromolecular compound, can also be from aminoacid, sulfur-bearing Reducing agent and antioxidant apoplexy due to endogenous wind select at least-kind add in the medicament that the present invention contains G-CSF.The hydrogen base acid of illustrating comprises glycine, threonyl, tryptophan, lysine, hydroxylysine, histidine, arginine, cysteine, cystine and methionine.The sulfur-bearing Reducing agent of being mentioned comprises N-acetylcystein, N-acetyl homocysteine, thioctic acid, thiodiglycol, sulfur ethanolamine, thioglycerin, the sulfur sorbitol, sulfur glycol acid and salt thereof, thiosulfate, sulfur hydracid sodium, sodium pyrosulfite, sodium sulfite, thiolactic acid, dithiothreitol, DTT, glutathion, with a kind of sulfur Reducing agent that has sulfydryl of gentleness, for example a kind of C 1-C 7The sulfur alkanoic acid.The antioxidant of being mentioned comprises, arabo-ascorbic acid, two butylated hydroxytoluene, anethole htpb, ae-α-tocopheronic acid, tocopherol acetate, L-ascorbic acid and salt thereof, L-ascorbic acid Petiolus Trachycarpi salt, L-ascorbic acid stearate, three amyl group gallates, propyl group gallate and chelating agen are disodiumedetate (EDTA) for example, tetrasodium pyrophosphate and Polymeric sodium metaphosphate..
Above-mentioned aminoacid, sulfur-bearing Reducing agent and antioxidant or its mixture is 1-10,000 part of every part of G-CSF dosage by weight.
Stabilization formulations in order to contain G-CSF with suitable dose form preparation the present invention can add following one or more reagent: diluent, cosolvent, isotonic agent, excipient, PH regulator, emollient and buffer.
Stable G of the present invention-CSF medicament both can have been prepared for oral use, also can non-intestinal usefulness, for example inject in many ways.The ad hoc fashion of taking has determined different dosage.Representative dosage forms comprises: be applicable to oral for example tablet, pill, capsule, granule and suspension, solution, suspension and cold dry preparation are mainly used in intravenous injection, intramuscular injection etc. down injection and wait in injection, be suitable for through mucosa take as rectal suppository, nasal drop and vaginal suppository.
According to the present invention, from surfactant, saccharide, at least can select a kind of adding in the medicament that contains G-CSF in protein or the macromolecular compound class material, so, can prevent to be adsorbed on chamber wall or the syringe simultaneously, and can in the long duration, keep stable.About utilizing above-mentioned substance to stablize G-CSF and preventing that the detailed mechanism of adsorbing from understanding fully.When surfactant exists, topped as the proteic G of mercapto water-CSF surface by surfactant institute, form soluble substance, so, a spot of G-CSF of plate also can prevent to be adsorbed on chamber wall and the syringe.Saccharide or hydrophilic macromolecular compound form the hydration layer between G-CSF and container and injector wall, therefore can effectively prevent to adsorb G-CSF.Albumen then and G-CSF competitive Adsorption on container and injector wall, therefore can effectively suppress the absorption of G-CSF.
Except preventing G-CSF absorption, above-mentioned substance also can prevent the combination or the polymerization of G-CSF molecule.Have surfactant, when saccharide, protein or macromolecular compound, single G-CSF molecular dispersion is in these materials, and the intermolecular interaction of G-CSF reduces greatly so that cause its in conjunction with or the remarkable minimizing of polymerizing power.In addition, these materials can stop the autoxidation process of quickening under high temperature and humidity, or anti-the oxidation combination or the polymerization that cause.Add a seed amino acid, sulfur-bearing Reducing agent or a kind of antioxidant can further strengthen and prevent G-CSF autoxidation, combination or polymeric effect.
The problems referred to above are worth paying special attention to injection solution and suspension, but for example in the process of tablet formulation G-CSF these problems are being arranged also with other dosage form.Add surfactant for latter event, saccharide, protein or macromolecular compound are also effective.
Be selected from surfactant by adding, saccharide, a kind of material of protein and macromolecular compound class, G-CSF is highly stable, can keep active for a long time, and this will be confirmed in the infra example.In order to reach this purpose, in these materials the quantity of each particularly its lower limit be crucial, following scope is ideal: each part G-CSF adds 1-10,000 portion of sugar, 1-20,000 part of protein and 1-20,000 part of macromolecular compound by weight.
According to the present invention, surfactant, saccharide, protein and/or macromolecular compound use by specific concentrations, and its effect is not only to prevent that G-CSF is adsorbed on container and the injector wall, and is to strengthen containing the stability of G-CSF medicament.Thereby just may ensure that patient takes a small amount of and is the G-CSF of height exact dose.Because G-CSF is very expensive, use will cause production to contain G-CSF medicament price reduction like this.
In order further to illustrate the present invention, provide following example, but this does not mean that as a kind of restriction.In these examples, adopt following any method can determine the residual activity of G-CSF.A) bone marrow cells in mice soft agar assay
Mix horse serum (0.4ml), 0.1 ml sample, 0.1ml C3H/H e(female) Os Mus myelocyte suspension (0.5-1 * 0.5 nucleus) and 0.4ml contain the 5A culture fluid of the modification MeCoy of 0.75% agar, side (35mm to the plastics plate of tissue culture φ) solidify, in 37 ℃ at 5%CO 2Cultivated 5 days under/95% air and 100% humidity.Calculate the colony number (colony contains at least 50 cells) that forms and measure activity, form a colony and be decided to be an active unit.
MeCoy5A culture fluid according to the modification of the following step compound method (a) usefulness.The 5A culture solution (double concentration) of the MeCoy that revises
The 5A culture fluid (Gibco) of 12 gram MeCoy, 2.55 gram MEM aminoacid-vitamin medium (Nissui Seiyaku company) 2.18 gram sodium bicarbonate and 50,000 unit potassium penicillin G is dissolved in for twice in 500 ml distilled waters, then, by microporous filter membrane (0.22um) aseptic filtration solution.(b) RPHPLC (reversed-phase high-performance liquid chromatography):
Use anti-phase C 8Post (4.6mm * 300mm, 5um) and normal propyl alcohol/trifluoracetic acid mixed liquor as mobile phase, under the condition of following gradient elution, determine the residual activity of G-CSF (injection is equivalent to the amount of 1 microgram): time (second) solvent (A) solvent (B) gradient
Figure C8710496300131
Solvent (A): 30% normal propyl alcohol and 0.1% trifluoracetic acid solvent (B): 60% normal propyl alcohol and 0.1% trifluoracetic acid
The detection wavelength is 210nm, and the active percentage rate of residue G-CSF calculates by following formula:
×100
The G of Ce Dinging-CSF surplus has good dependency with the result who records with bone marrow cells in mice soft agar method (a) in this way.Example 1
A kind of stabilizing agent that table 1 is listed adds among 5 microgram G-CSF, (contains 100mM chloro sodium, PH7.4), makes every milliliter of medicament that contains 5 microgram G-CSF, cold then doing in the aseptic 20mM of the being dissolved in buffer of mixture.According to G-CSF activity change that the time presented, usefulness method (a) is measured, and the results are shown in Table 1.The residual activity of G-CSF that term " active (%) " representative is relevant with initial unit, with following formulate:
Cold driedly carry out with the following step:
G-CSF the solution that contains stability is put into sulfanilamide handled the disinfectant vial, at-40 ℃ or be lower than-40 ℃ freezing 4 hours, then carry out dry 48 hours of the first time, be heated to 0 ℃ from-40 ℃, pressure increases to 0.1 holder from 0.03 holder, carry out dry 12 hours of the second time then, temperature is heated to 20 ℃ from 0 ℃, pressure increases to 0.08 holder from 0.03 holder, then the disinfectant drying nitrogen is charged into bottle inside, make it reach an atmospheric pressure, bottle seals with aluminium lid with cold dried rubber closure beyond the Great Wall at last.Table 1
Stabilizing agent Quantity (by weight) Active (%)
Preserve after 6 months for 4 ℃ Preserve after 1 month for 37 ℃
Xylitol mannitol glucuronic acid hyaluronic acid glucan (m.w.40; 000) the white polyethylene glycol (m.w.4 of gelatin collagen dawn of the acid-treated gelatin alkali treatment of white man's serum globulins of clear dawn of heparin chitosan alginic acid human serum; 000) hydroxypropyl cellulose sodium carboxymethylcellulose CMC polyvinyl alcohol (m.w.50; 000) polyvinylpyrrolidone (m.w.50,000) 10,000 10,000 10,000 2,000 2,000 5,000 2,000 2,000 1,000 1,000 2,000 1,000 2,000 10,000 1,000 1,000 5,000 2,000 2,000 92 91 86 92 95 85 93 90 98 98 97 99 95 94 98 88 92 96 95 86 85 82 89 90 80 91 90 99 95 95 96 90 90 94 80 90 95 94
White mannitol cysteine of clear dawn of human serum 2,000 2,000 100 100 97
Table 1 (continuing)
Stabilizing agent Quantity (by weight) Active (%)
Preserve after 6 months for 4 ℃ Preserve after 1 month for 37 ℃
White polyoxyethylene sorbitan monolaurate mannitol of clear dawn of human serum 2,000 100 2,000 99 96
White hydroxypropyl cellulose glucosan of clear dawn of human serum (m.w.40,000) 2,000 500 2,000 98 92
Polyoxyethylene sorbitan lauric acid Sorbitol 100 2,000 98 96
The hard Oleum Ricini glucosan of polyoxyethylene (m.w.40,000) 100 2,000 94 92
Do not add - 74 58
Example 2
Add a kind of stabilizing agent of listing in table 2 to 10 micrograms G-CSF, to (contain 100mM sodium chloride in the aseptic 20mM of the being dissolved in phosphate buffer of mixture, PH7.4) preparation becomes every milliliter of medicament that contains 10 microgram G-CSF, in the vial that the aseptic sulfanilamide of packing into of preparation was handled, seal, be prepared into G-CSF solution.Adopt the same quadrat method of example 1 to measure in the solution, the results are shown in table 2 along with the activity change of time G-CSF.
Table 2
Stabilizing agent Quantity (by weight) Active (%)
Preserve after 7 days for 4 ℃ 4 ℃ preserve February after Room temperature preservation is after January
Mannitol hyaluronic acid glucan (m.w.40; 000) white polyethylene glycol (m.w.4 of glycerine neuraminic acid chitin dextrin human serum white man's serum globulins of clear dawn acid treatment gelatin alkali treatment gelatin collagen dawn; 000) hydroxypropyl cellulose sodium carboxymethylcellulose hydroxyethylcellulose polyvinyl alcohol (m.w.50; 000) polyvinylpyrrolidone (m.w.50,000) sorbitan monolaurate Tween 20 5,000 2,000 2,000 10,000 5,000 2,000 2,000 1,000 1,000 2,000 500 2,000 10,000 2,000 2,000 4,000 4,000 4,000 400 400 91 93 96 90 93 95 90 99 98 97 99 99 94 98 92 92 97 95 97 100 87 87 95 90 91 92 92 95 94 96 95 94 89 95 91 94 93 95 96 96 82 70 85 88 84 86 87 92 90 87 92 88 90 92 80 90 90 92 95 94
Table 2 (continuing)
Stabilizing agent Quantity (by weight) Active (%)
Preserve after 7 days for 4 ℃ 4 ℃ preserve February after Room temperature preservation is after January
Polyoxyethylene sorbitan single-stearic hydrochlorate polyoxyethylene, the hard Oleum Ricini dodecyl sodium sulfate of polyoxypropylene glycol ether polyoxyethylene lecithin 400 400 400 2,000 2,000 98 100 99 97 97 97 94 98 93 94 94 93 90 87 90
White mannitol cysteine of clear dawn of human serum 2,000 2,000 100 100 99 97
White polyoxyethylene sorbitan monolaurate mannitol of clear dawn of human serum 2,000 100 2,000 99 97 95
White hydroxypropyl cellulose glucosan of clear dawn of human serum (m.w.40,000) 1,000 500 2,000 99 97 95
Polyoxyethylene sorbitan monopalmitate Sorbitol 100 2,000 96 96 93
The hard Oleum Ricini glucosan of polyoxyethylene (m.w.40,000) 100 2,000 95 92 92
Do not add - 72 61 47
Example 3
Add a kind of stabilizing agent of listing in table 3 to 10 micrograms G-CSF, will (contain 100mM sodium chloride, PH7.4) be prepared into every milliliter of medicament that contains 10 microgram G-CSF in the aseptic 20mM of the being dissolved in phosphate buffer of mixture.1 ml of formulation is added in the silication vial that sulfanilamide handled, place 4 ℃.Every kind of stabilizing agent prevents that effect that G-CSF absorbs can be by in half an hour, after 2 hours and 4 hours in the mensuration solution G-CSF retentive activity estimate.Measure and adopt the method for (b) used reverse phase HPLC to carry out, the results are shown in table 3.
Table 3
Stabilizing agent Quantity (by weight) Retentive activity (%)
Beginning Half an hour 2 hours 24 hours
Mannitol hyaluronic acid glucan (m.w.40; 000) white polyethylene glycol (m.w.4 of glycerine heparin glucuronic acid glucose ketone acid clear dawn of human serum white man's serum globulins alkali treatment gelatin acid treatment gelatin collagen dawn; 000) the plain sodium carboxymethylcellulose hydroxyethylcellulose of hydroxypropyl cellulose polyvinyl alcohol (m.w.50; 000) the hard castor mushroom of polyvinylpyrrolidone (m.w.50,000) suction D-sorbite list caprylate polyoxyethylene sorbitan monostearate polyoxyethylene oil 5,000 2,000 2,000 10,000 2,000 5,000 5,000 1,000 1,000 500 2,000 2,000 10,000 2,000 2,000 4,000 4,000 4,000 400 400 400 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 93 97 98 94 92 96 92 100 98 99 99 100 100 100 98 96 99 98 100 100 99 90 92 95 91 90 90 88 101 100 98 97 98 100 100 96 93 100 98 100 98 101 91 92 96 90 90 91 90 99 98 99 97 99 99 99 95 92 98 96 98 100 99
Table 3 (continuing)
Stabilizing agent Quantity (by weight) Retentive activity (%)
Beginning Half an hour 2 hours 24 hours
Dodecyl sodium sulfate lecithin 2,000 2,000 100 100 100 99 99 100 97 98
White mannitol cysteine of clear dawn of human serum 2,000 2,000 100 100 100 100 101
White polyoxyethylene sorbitan monolaurate mannitol of clear dawn of human serum 2,000 100 2,000 100 100 98 99
White hydroxypropyl cellulose glucosan of clear dawn of human serum (m.w.40,000) 1,000 500 2,000 100 101 99 100
Polyoxyethylene sorbitan monolaurate Sorbitol 100 2,000 100 100 99 99
The hard Oleum Ricini glucosan of polyoxyethylene (m.w.40,000) 100 2,000 100 100 98 97
Do not add - 100 91 72 73

Claims (1)

1. a production contains the method for the medicament of stable granulocytosis colony stimulative factor, this method comprises: under 1-30 ℃ temperature conditions with granulocytosis colony stimulative factor (G-CSF) be selected from dehydration pears sugar alcohol fatty acid ester, polyoxyethylene sorbitan fatty acid esters, cithrol, polyoxyethylene polyoxy-propylene, polyoxy ethylization hardened castor oil, alkyl sulfate, lecithin, glycerol, xylitol, Sorbitol, mannitol, glucuronic acid, neuraminic acid, ketogluconic acid, hyaluronic acid and its salt, heparin, chitin and derivant thereof, chitosan and derivant thereof, dextrin, mean molecule quantity is 5,000-150,000 glucosan, alginic acid and salt thereof, the human serum albumin, the human serum globulin, gelatin, mean molecule quantity is 7,000-100,000 the acid or the gelatin of alkali treatment, collagen protein, hydroxypropyl cellulose, hydroxy methocel, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, molecular weight is 300-6,000 Polyethylene Glycol, molecular weight is 20,000-100,000 polyvinyl alcohol, molecular weight is 20,000-100, at least a material of 000 polyvinylpyrrolidone mixes, then the mixture that produces is dissolved in a kind of buffer, and this solution packed in the container, wherein said G-CSF has following character:
(i) molecular weight: carrying out electrophoresis in coagulating by dodecyl sodium sulfate-polyacrylamide, to record molecular weight be 19,000 ± 1000;
(ii) isoelectric point, IP: have at least one in the following isoelectric point, IP.
pI＝5.5±0.1，pI＝5.8±0.1，pI＝6.1±0.1。
CN87104963A 1986-07-18 1987-07-18 Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing same Expired - Lifetime CN1033738C (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP169489/86 1986-07-18
JP16948886 1986-07-18
JP16948986 1986-07-18
JP169487/86 1986-07-18
JP169486/86 1986-07-18
JP16948786 1986-07-18
JP16948686 1986-07-18
JP169488/86 1986-07-18

Publications (2)

Publication Number Publication Date
CN87104963A CN87104963A (en) 1988-02-24
CN1033738C true CN1033738C (en) 1997-01-08

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
CN87104963A Expired - Lifetime CN1033738C (en) 1986-07-18 1987-07-18 Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing same

Country Status (24)

Country Link
KR (1) KR930004597B1 (en)
CN (1) CN1033738C (en)
AT (1) AT402259B (en)
AU (1) AU611856B2 (en)
BE (1) BE1000253A3 (en)
CA (1) CA1297007C (en)
CH (1) CH671157A5 (en)
DE (1) DE3723781C2 (en)
DK (1) DK171308B1 (en)
ES (1) ES2010226A6 (en)
FR (1) FR2601591B1 (en)
GB (1) GB2193631B (en)
GR (1) GR871067B (en)
HK (1) HK64893A (en)
HU (1) HU198627B (en)
IE (1) IE60290B1 (en)
IL (1) IL83220A (en)
IT (1) IT1218927B (en)
NL (1) NL192917C (en)
NO (1) NO171828C (en)
PT (1) PT85343B (en)
SE (1) SE503312C2 (en)
SG (1) SG64393G (en)
YU (1) YU47543B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NO179479C (en) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Process for the preparation of an intravaginal pharmaceutical preparation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (en) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Oral preparation containing bioactive protein
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686900B1 (en) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2693907B1 (en) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa A method of administering granulocyte colony stimulating factor solutions.
EP0582932A1 (en) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutic system for the parenteral administration of hematopoietic growth factors
DE4242919A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Process for the preparation of storage-stable aqueous pharmaceutical preparations of G-CSF
DE4242863A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
WO1999044630A1 (en) * 1998-03-06 1999-09-10 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
ATE389414T1 (en) 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd STABLE PROTEIN SOLUTION BOTTLED IN A CONTAINER MADE OF HYDROPHOBIC RESIN AND A METHOD FOR STABILIZING THE SAME
EP1260230A4 (en) * 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd Preparations stabilized over long time
PT1129720E (en) * 2000-02-29 2004-08-31 Pfizer Prod Inc STABILIZED GRANULOCYTE COLONY STIMULATOR FACTOR
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CA2420850A1 (en) * 2000-09-01 2003-02-28 Chugai Seiyaku Kabushiki Kaisha Solution formulations having long-term stability
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425738T3 (en) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2004020462A1 (en) 2002-08-27 2004-03-11 Fujii, Nobutaka Cxcr4 antagonist and use thereof
EP1598074B1 (en) 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
DE202006020194U1 (en) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF liquid formulation
CA2673719C (en) 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
AU2011207915B2 (en) 2010-01-19 2013-07-11 Hanmi Science Co., Ltd. Liquid formulations for long-acting G-CSF conjugate
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
BR112018000903A2 (en) 2015-07-16 2018-09-11 Biokine Therapeutics Ltd. compositions and methods for cancer treatment
KR102033920B1 (en) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 How to treat acute myeloid leukemia
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
EP3797752A4 (en) * 2018-05-21 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass vial

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (en) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Stabilising protein during separation, purification and storage - by adding amphiphilic cpds., esp. lipid(s), ionic and or nonionic detergents
AU523077B2 (en) * 1978-03-20 1982-07-08 Green Cross Corporation, The Hgi glycoprotein
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
JPS60228422A (en) * 1984-04-26 1985-11-13 Suntory Ltd Stabilized preparation of physiologically active substance
JPS61227526A (en) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd Novel csf and method of collecting same
JPS6191131A (en) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd Method and composition for preventing adsorption of pharmaceutical
ATE80894T1 (en) * 1985-02-05 1992-10-15 Cetus Oncology Corp PURIFICATION OF NATURAL COLONY STIMULATING FACTOR-1.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (en) * 1985-10-04 1994-03-16 中外製薬株式会社 Leukopenia treatment

Also Published As

Publication number Publication date
ES2010226A6 (en) 1989-11-01
HK64893A (en) 1993-07-16
FR2601591A1 (en) 1988-01-22
HU198627B (en) 1989-11-28
FR2601591B1 (en) 1991-04-26
IT1218927B (en) 1990-04-24
DK368387D0 (en) 1987-07-15
SG64393G (en) 1993-08-06
AT402259B (en) 1997-03-25
YU134287A (en) 1989-06-30
IE60290B1 (en) 1994-06-29
BE1000253A3 (en) 1988-09-27
AU611856B2 (en) 1991-06-27
SE8702907L (en) 1988-01-19
SE8702907D0 (en) 1987-07-17
ATA177587A (en) 1996-08-15
DE3723781A1 (en) 1988-01-21
PT85343A (en) 1987-08-01
DK171308B1 (en) 1996-09-02
NO872966L (en) 1988-01-19
NL192917C (en) 1998-05-07
NO171828B (en) 1993-02-01
KR880001297A (en) 1988-04-22
HUT44941A (en) 1988-05-30
CA1297007C (en) 1992-03-10
CN87104963A (en) 1988-02-24
NO171828C (en) 1993-05-12
IL83220A0 (en) 1987-12-31
IE871933L (en) 1988-01-18
IL83220A (en) 1993-01-31
AU7566587A (en) 1988-01-21
CH671157A5 (en) 1989-08-15
NL8701640A (en) 1988-02-16
NO872966D0 (en) 1987-07-16
NL192917B (en) 1998-01-05
KR930004597B1 (en) 1993-06-01
PT85343B (en) 1990-04-30
GB8716904D0 (en) 1987-08-26
DE3723781C2 (en) 1999-09-02
SE503312C2 (en) 1996-05-13
GB2193631B (en) 1990-11-21
YU47543B (en) 1995-10-03
DK368387A (en) 1988-01-19
GR871067B (en) 1987-11-19
GB2193631A (en) 1988-02-17
IT8767594A0 (en) 1987-07-10

Similar Documents

Publication Publication Date Title
CN1033738C (en) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing same
EP1180368B1 (en) Freeze dried hgf preparations
US20090247450A1 (en) G-csf liquid formulation
JP3927248B2 (en) HGF lyophilized formulation
JP3283288B2 (en) Bioactive peptide preparation
JP2577744B2 (en) Stable granulocyte colony-stimulating factor containing preparation
US5714458A (en) Stable pharmaceutical compositions containing a fibroblast growth factor
EP0539408B1 (en) Stable pharmaceutical compositions containing a fibroblast growth factor
WO1993005799A1 (en) Lyophilized stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
JP2577742B2 (en) Stable granulocyte colony-stimulating factor containing preparation
US5534251A (en) Stabilized il-1α medicinal composition
JPS63146828A (en) Stable granulocyte colony stimulating factor-containing preparation
JP2577743B2 (en) Stable granulocyte colony-stimulating factor containing preparation
JPH0361652B2 (en)
JP2629000B2 (en) Stable granulocyte colony stimulating factor-containing preparation
JP3655645B2 (en) Transmucosal agent
JP3181391B2 (en) Formulation for nasal administration
JPH0378847B2 (en)
JPS61197527A (en) Interleukin-2 composition
CN1280856A (en) Composition of stable bioactive substances and its preparing process
KR20060108040A (en) Hg-csf aqueous formulation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term